Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines
Open Access
- 1 November 2002
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 100 (9) , 3287-3294
- https://doi.org/10.1182/blood-2002-01-0231
Abstract
Sézary syndrome (SzS) is an advanced form of cutaneous T-cell lymphoma associated with involvement of the peripheral blood by malignant T cells. The disease is defined by impaired cell-mediated immunity and the production of interferon-γ (IFN-γ) and interleukin-2 (IL-2), possibly as a result of deficient IL-12 production. To understand the mechanism of this impairment, we examined the composition and function of dendritic cells and monocytes in the blood of SzS patients with different levels of peripheral blood tumor burden. Consistent with our previous observations, numbers of monocytes in SzS patients were comparable to numbers observed in healthy donors. In contrast, decreased IL-12 production correlated with a decrease in the numbers of CD11c+ dendritic cells, which was particularly profound among patients with medium (20%-50% circulating malignant T cells) and high (more than 50% circulating malignant T cells) tumor burden. Furthermore, CD123+ dendritic cells, major producers of IFN-α, were significantly diminished in SzS patients, regardless of the level of tumor burden. Granulocyte macrophage–colony-stimulating factor–treated patients experienced an increase in the number of dendritic cells but not in IFN-α or IL-12 production. However, in vitro stimulation of peripheral blood mononuclear cells from SzS patients with rCD40L and IFN-γ significantly increased the production of IL-12. Thus, our results demonstrate a profound defect in circulating dendritic cells in SzS patients that may contribute to the pathogenesis of the cytokine disorders and to the depressed cellular immunity. Importantly, the ability of rCD40L to potently induce IL-12 production from monocytes and residual dendritic cells of SzS patients could potentially serve as an immune-restorative therapeutic agent.Keywords
This publication has 60 references indexed in Scilit:
- Dysregulation of Lymphocyte Interleukin-12 Receptor Expression in Sézary SyndromeJournal of Investigative Dermatology, 2001
- Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: Comparative analysis of different stimuli, secretion-blocking agents and incubation periodsCytometry, 2001
- CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunitySeminars in Immunology, 1998
- The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-LigandThe Journal of Experimental Medicine, 1997
- Th2 Cytokine Profile in Cutaneous T-Cell LymphomaJournal of Investigative Dermatology, 1995
- Activated T cells induce interleukin‐12 production by monocytes via CD40‐CD40 ligand interactionEuropean Journal of Immunology, 1995
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- Cell Surface Differentiation Antigens of the Malignant T Cell in Sezary Syndrome and Mycosis FungoidesJournal of Clinical Investigation, 1981